TY  - GEN
AU  - Santos,Fabio P S
AU  - Kantarjian,Hagop M
AU  - Jain,Nitin
AU  - Manshouri,Taghi
AU  - Thomas,Deborah A
AU  - Garcia-Manero,Guillermo
AU  - Kennedy,Debra
AU  - Estrov,Zeev
AU  - Cortes,Jorge
AU  - Verstovsek,Srdan
TI  - Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
SN  - 1528-0020
PY  - 2010///0319
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Blotting, Western
KW  - Carbazoles
KW  - therapeutic use
KW  - Cytokines
KW  - metabolism
KW  - Female
KW  - Furans
KW  - Humans
KW  - Janus Kinase 2
KW  - antagonists & inhibitors
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Polycythemia Vera
KW  - complications
KW  - Primary Myelofibrosis
KW  - Prognosis
KW  - Protein-Tyrosine Kinases
KW  - Survival Rate
KW  - Thrombocythemia, Essential
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2009-10-246363
ER  -